JP2023524666A5 - - Google Patents
Info
- Publication number
- JP2023524666A5 JP2023524666A5 JP2022565535A JP2022565535A JP2023524666A5 JP 2023524666 A5 JP2023524666 A5 JP 2023524666A5 JP 2022565535 A JP2022565535 A JP 2022565535A JP 2022565535 A JP2022565535 A JP 2022565535A JP 2023524666 A5 JP2023524666 A5 JP 2023524666A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063016913P | 2020-04-28 | 2020-04-28 | |
| US63/016,913 | 2020-04-28 | ||
| US202063121781P | 2020-12-04 | 2020-12-04 | |
| US63/121,781 | 2020-12-04 | ||
| US202063124058P | 2020-12-11 | 2020-12-11 | |
| US63/124,058 | 2020-12-11 | ||
| US202063130100P | 2020-12-23 | 2020-12-23 | |
| US63/130,100 | 2020-12-23 | ||
| US202163165619P | 2021-03-24 | 2021-03-24 | |
| US63/165,619 | 2021-03-24 | ||
| US202163176221P | 2021-04-17 | 2021-04-17 | |
| US63/176,221 | 2021-04-17 | ||
| PCT/US2021/029446 WO2021222287A2 (en) | 2020-04-28 | 2021-04-27 | Methods of in vitro cell delivery |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023524666A JP2023524666A (ja) | 2023-06-13 |
| JPWO2021222287A5 JPWO2021222287A5 (https=) | 2025-02-20 |
| JP2023524666A5 true JP2023524666A5 (https=) | 2025-02-20 |
Family
ID=76270024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022565535A Pending JP2023524666A (ja) | 2020-04-28 | 2021-04-27 | インビトロ細胞送達の方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230183753A1 (https=) |
| EP (1) | EP4143304A2 (https=) |
| JP (1) | JP2023524666A (https=) |
| KR (1) | KR20230017783A (https=) |
| CN (1) | CN116018403A (https=) |
| AU (1) | AU2021263745A1 (https=) |
| BR (1) | BR112022021676A2 (https=) |
| CA (1) | CA3181340A1 (https=) |
| CL (1) | CL2022002974A1 (https=) |
| IL (1) | IL297550A (https=) |
| MX (1) | MX2022013403A (https=) |
| TW (1) | TW202204612A (https=) |
| WO (1) | WO2021222287A2 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023549011A (ja) | 2020-09-15 | 2023-11-22 | ヴァーヴ・セラピューティクス，インコーポレーテッド | 遺伝子編集のための脂質製剤 |
| IL303195A (en) | 2020-11-25 | 2023-07-01 | Akagera Medicines Inc | Lipid nanoparticles for delivery of nucleic acids and related methods of use |
| AU2021409732A1 (en) * | 2020-12-23 | 2023-07-20 | Intellia Therapeutics, Inc. | Compositions and methods for reducing hla-a in a cell |
| JP2024505672A (ja) | 2021-02-08 | 2024-02-07 | インテリア セラピューティクス，インコーポレイテッド | 免疫療法のためのナチュラルキラー細胞受容体２ｂ４組成物及び方法 |
| WO2022170194A2 (en) | 2021-02-08 | 2022-08-11 | Intellia Therapeutics, Inc. | Lymphocyte activation gene 3 (lag3) compositions and methods for immunotherapy |
| JP2024506016A (ja) | 2021-02-08 | 2024-02-08 | インテリア セラピューティクス，インコーポレイテッド | 免疫療法のためのｔ細胞免疫グロブリン及びムチンドメイン３（ｔｉｍ３）組成物及び方法 |
| KR20240032013A (ko) | 2021-06-10 | 2024-03-08 | 인텔리아 테라퓨틱스, 인크. | 유전자 편집을 위한 내부 링커를 포함하는 변형된 가이드 rna |
| WO2023274386A1 (zh) * | 2021-07-01 | 2023-01-05 | 宁波茂行生物医药科技有限公司 | 靶向egfr的通用型car-t细胞及其制备方法 |
| EP4392060A1 (en) | 2021-08-24 | 2024-07-03 | Intellia Therapeutics, Inc. | Programmed cell death protein 1 (pd1) compositions and methods for cell-based therapy |
| GB202117583D0 (en) * | 2021-12-06 | 2022-01-19 | Cambridge Entpr Ltd | Protein expression |
| US20250049850A1 (en) * | 2021-12-15 | 2025-02-13 | Regents Of The University Of Minnesota | Non-viral b cell engineering methods |
| CN117004604A (zh) * | 2022-04-28 | 2023-11-07 | 南京北恒生物科技有限公司 | 一种ciita基因被敲除的工程化免疫细胞及其用途 |
| EP4531819A2 (en) | 2022-05-25 | 2025-04-09 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof |
| CN119384498A (zh) * | 2022-06-16 | 2025-01-28 | 因特利亚治疗公司 | 用于对细胞进行遗传修饰的方法和组合物 |
| CN119585419A (zh) | 2022-06-29 | 2025-03-07 | 因特利亚治疗公司 | 工程化t细胞 |
| CN119730863A (zh) * | 2022-08-10 | 2025-03-28 | 普洛迈博生物技术公司 | 用car rna-lnp转染的nk细胞 |
| WO2024118634A2 (en) * | 2022-11-28 | 2024-06-06 | The Trustees Of The University Of Pennsylvania | In vivo expansion of car t cells and delivery of car target antigen to tumors using mrna lipid nanoparticles |
| WO2024137766A2 (en) | 2022-12-21 | 2024-06-27 | Intellia Therapeutics, Inc. | Compositions and methods for proprotein convertase subtilisin kexin 9 (pcsk9) editing |
| WO2024138189A2 (en) | 2022-12-22 | 2024-06-27 | Intellia Therapeutics, Inc. | Methods for analyzing nucleic acid cargos of lipid nucleic acid assemblies |
| WO2024186890A1 (en) | 2023-03-06 | 2024-09-12 | Intellia Therapeutics, Inc. | Compositions and methods for hepatitis b virus (hbv) genome editing |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025137301A1 (en) * | 2023-12-20 | 2025-06-26 | Intellia Therapeutics, Inc. | Methods for rapid engineering of cells |
| WO2025137439A2 (en) | 2023-12-20 | 2025-06-26 | Intellia Therapeutics, Inc. | Engineered t cells |
| WO2025184520A1 (en) | 2024-02-29 | 2025-09-04 | Intellia Therapeutics, Inc. | Compositions and methods for angiopoietin like 3 (angptl3) editing |
| WO2025217892A1 (zh) * | 2024-04-19 | 2025-10-23 | 深圳市先康达生命科学有限公司 | 多位点同时敲入dna片段的基因编辑方法及其应用 |
| WO2025244134A1 (en) * | 2024-05-24 | 2025-11-27 | Fujifilm Corporation | Method to deliver a payload to cells, and lipid composition |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| KR940703846A (ko) | 1991-12-24 | 1994-12-12 | 비. 린네 파샬 | 갭(gap)이 형성된 2′ 변성된 올리고뉴클레오티드(gapped 2′ modifed oligonucleotides) |
| US6169169B1 (en) | 1994-05-19 | 2001-01-02 | Dako A/S | PNA probes for detection of Neisseria gonorrhoeae and Chlamydia trachomatis |
| GB0119865D0 (en) | 2001-08-14 | 2001-10-10 | Cancer Res Campaign Tech | DNA-PK inhibitors |
| WO2006007712A1 (en) | 2004-07-19 | 2006-01-26 | Protiva Biotherapeutics, Inc. | Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents |
| WO2011091324A2 (en) | 2010-01-22 | 2011-07-28 | The Scripps Research Institute | Methods of generating zinc finger nucleases having altered activity |
| CN103668470B (zh) | 2012-09-12 | 2015-07-29 | 上海斯丹赛生物技术有限公司 | 一种dna文库及构建转录激活子样效应因子核酸酶质粒的方法 |
| DK2931898T3 (en) | 2012-12-12 | 2016-06-20 | Massachusetts Inst Technology | CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| CA2895155C (en) | 2012-12-17 | 2021-07-06 | President And Fellows Of Harvard College | Rna-guided human genome engineering |
| EP3608308B1 (en) | 2013-03-08 | 2021-07-21 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| SI3527563T1 (sl) | 2013-03-12 | 2022-01-31 | Vertex Pharmaceuticals Incorporated | Inhibitorji DNA-PK |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| ES2895651T3 (es) | 2013-12-19 | 2022-02-22 | Novartis Ag | Lípidos y composiciones lipídicas para la administración de agentes activos |
| EP3169309B1 (en) | 2014-07-16 | 2023-05-10 | Novartis AG | Method of encapsulating a nucleic acid in a lipid nanoparticle host |
| TWI773666B (zh) | 2016-03-30 | 2022-08-11 | 美商英特利亞醫療公司 | Crispr/cas 組分之脂質奈米粒子調配物 |
| WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| EP3551169A4 (en) * | 2016-12-09 | 2020-09-09 | Sangamo Therapeutics, Inc. | TARGET-SPECIFIC NUCLEASES ADMINISTRATION |
| SMT202100225T1 (it) | 2016-12-20 | 2021-05-07 | Astrazeneca Ab | Composti di ammino-triazolopiridina e loro uso nel trattamento del cancro |
| MX2019013514A (es) * | 2017-05-12 | 2020-01-20 | Crispr Therapeutics Ag | Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia. |
| PT3688162T (pt) | 2017-09-29 | 2024-04-23 | Intellia Therapeutics Inc | Formulações |
| BR112020006256A2 (pt) * | 2017-09-29 | 2020-10-20 | Intellia Therapeutics, Inc. | método in vitro de administração de mrna usando nanopartículas de lipídio |
| WO2019147805A2 (en) | 2018-01-26 | 2019-08-01 | The Board Of Trustees Of The Leland Stanford Junior University | Regulatory t cells targeted with chimeric antigen receptors |
| CN112292139B (zh) * | 2018-03-13 | 2024-03-08 | 明尼苏达大学董事会 | 使用Cas9碱基编辑器的淋巴造血改造 |
| WO2020072605A1 (en) | 2018-10-02 | 2020-04-09 | Intellia Therapeutics, Inc. | Ionizable amine lipids |
| IL314386A (en) | 2018-12-05 | 2024-09-01 | Intellia Therapeutics Inc | amine modified lipids |
| WO2020219876A1 (en) | 2019-04-25 | 2020-10-29 | Intellia Therapeutics, Inc. | Ionizable amine lipids and lipid nanoparticles |
-
2021
- 2021-04-27 KR KR1020227041443A patent/KR20230017783A/ko active Pending
- 2021-04-27 WO PCT/US2021/029446 patent/WO2021222287A2/en not_active Ceased
- 2021-04-27 CA CA3181340A patent/CA3181340A1/en active Pending
- 2021-04-27 IL IL297550A patent/IL297550A/en unknown
- 2021-04-27 MX MX2022013403A patent/MX2022013403A/es unknown
- 2021-04-27 AU AU2021263745A patent/AU2021263745A1/en active Pending
- 2021-04-27 BR BR112022021676A patent/BR112022021676A2/pt unknown
- 2021-04-27 CN CN202180044410.4A patent/CN116018403A/zh active Pending
- 2021-04-27 TW TW110115207A patent/TW202204612A/zh unknown
- 2021-04-27 EP EP21729978.3A patent/EP4143304A2/en active Pending
- 2021-04-27 JP JP2022565535A patent/JP2023524666A/ja active Pending
-
2022
- 2022-10-26 CL CL2022002974A patent/CL2022002974A1/es unknown
- 2022-10-27 US US18/050,333 patent/US20230183753A1/en active Pending